• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

    3/31/25 1:39:56 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email

    SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT.

    To access the call today:

    Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730 and ask to be connected to the BioCardia call. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fyO2WNaO.

    A webcast replay of the call will be available approximately one hour after the end of the call at the above links. To access the replay internationally, please use the link https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6220156.



    Media Contact:
    Miranda Peto, Marketing / Investor Relations
    Email: [email protected]
    Phone: 650-226-0120
    
    Investor Contact:
    David McClung, Chief Financial Officer
    Email: [email protected]
    Phone: 650-226-0120

    Primary Logo

    Get the next $BCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

      SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will share recent business developments on the Company's therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure. Fire

      5/21/25 8:30:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

      SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fra

      5/14/25 4:05:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Altman Peter bought $221 worth of shares (100 units at $2.21), increasing direct ownership by 0.07% to 141,766 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/30/25 8:55:15 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $4,651 worth of shares (2,300 units at $2.02), increasing direct ownership by 2% to 141,666 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/22/25 6:45:25 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $1,028 worth of shares (400 units at $2.57), increasing direct ownership by 0.29% to 139,366 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/16/25 5:31:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Altman Peter bought $221 worth of shares (100 units at $2.21), increasing direct ownership by 0.07% to 141,766 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/30/25 8:55:15 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $4,651 worth of shares (2,300 units at $2.02), increasing direct ownership by 2% to 141,666 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/22/25 6:45:25 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $1,028 worth of shares (400 units at $2.57), increasing direct ownership by 0.29% to 139,366 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/16/25 5:31:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioCardia Inc.

      SC 13G - BioCardia, Inc. (0000925741) (Subject)

      9/6/24 7:45:48 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      4/5/24 4:13:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      2/27/24 4:53:40 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by BioCardia Inc.

      SCHEDULE 13D - BioCardia, Inc. (0000925741) (Subject)

      5/22/25 6:18:07 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/14/25 4:09:25 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by BioCardia Inc.

      10-Q - BioCardia, Inc. (0000925741) (Filer)

      5/14/25 4:05:54 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Financials

    Live finance-specific insights

    See more
    • BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

      SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fra

      5/14/25 4:05:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

      SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have no

      3/31/25 1:39:56 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BioCardia with a new price target

      HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

      12/20/21 6:05:04 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia downgraded by Dawson James

      Dawson James downgraded BioCardia from Buy to Neutral

      4/16/21 7:22:02 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care